Table 2.
Summary of the double blind placebo controlled study for naltrexone in pathological gambling.
| Study | Diagnostic Inclusion |
Exclusion Criteria
Personality Disorders and Axis I Disorders, |
Length (Weeks) | Dosage | N/completers | Efficacy/assessment | Tolerance |
|---|---|---|---|---|---|---|---|
| Kim 2001 | DSM IV | Yes | 11 | Mean 188mg/day | 83/45 | Yes CGI patient and clinician rated, G-SAS | Nausea, dry mouth, vivid dream, elevated transaminases |
| Grant 2008 | DSM IV | Yes | 18 | 50 -100- 150mg/day | 77/49 | Yes CGI PG-YBOCS No difference between doses |
No difference |
| Toneatto 2009 | DSM IV for pathological gambling and alcohol use disorder | No | 12 | Mean 59mg/day + cognitive behavioral therapy |
52/38 | No on frequency of gambling episode | Nausea |
| Porchet 2013 | 5 lifetime gambling experience | Yes | Slot machine task | 50mg/day Other group 2mg/day haloperidol |
62 | Yes on modulation of gambling distortions | |
| Kovanen 2016 | DSM IV | Yes | 20 | 50mg as needed | 101/69 | No PG-YBOCS | No difference |